Archived News Articles


05/11/2016 - Kineta wins $7.2M award to develop antiviral drug focused on Lassa fever, GeekWire

05/05/2016 - Seattle biotech Kineta wins $7.2M award for drug development, Puget Sound Business Journal

02/16/2016 - Work on Broad-Spectrum Drug to Treat Viruses Like Zika, Hepatitis C Speeds Up, Hepatitis News Today

02/06/2016 - As Zika rages, Seattle scientists step up antiviral drug research, Seattle Times

02/02/2016 - Local research could cure Zika virus and the common cold, KOMO News


12/16/2015 - Compound found to trigger innate immunity against viruses, NewsBeat UW Health Sciences

11/9/2015 - Snail venom discovery at Utah school could lead to safer painkillers, The Salt Lake Tribune

10/2/2015 - Kineta develops new pain med for soldiers, Puget Sound Business Journal

9/30/2015 - Seattle scientists developing non-addictive pain drug, KOMO News

9/28/2015 - Kineta Wins $1.1M U.S. Army Contract Toward Non-Opioid Pain Drug Development, GEN News

7/30/2015 - Kineta wins $4M award to develop therapies against viral diseases like Ebola, influenza, others, GeekWire

7/30/2015 - Seattle biotech Kineta lands $4M contract to develop immunotherapy for infectious disease, Puget Sound Business Journal

5/22/2015 - Kineta and partners raising funds to 'break out of the old biotech model', GeekWire

5/12/2015 - New drug shows promise against autoimmune diseases, KOMO 4 News

5/5/2015 - Seattle's Kineta announces promising results for new autoimmune drug, King 5 News

5/5/2015 - Novel Drug From Nature Shows Early Promise, Wall Street Journal

4/21/2015 - Seattle biotech teams with UW to ramp up drug discoveries, Puget Sound Business Journal

4/21/2015 - Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease, Business Wire

4/21/2015 - Wave of the future: The Ebola crisis as a tipping point for pharmaceutical R&D, BioPharma Dive

4/20/2015 - Scientists Target New Painkillers From Spider Venom, Wall Street Journal

4/9/2015 - Kineta’s Adjuvants Boost Flu Vaccine Effectiveness in Data Presented at World Vaccine Congress, Business Wire

3/26/2015 - Kineta’s Novel Antiviral Compounds Inhibit Broad Array of Emerging and Current Viruses Including Ebola, Business Wire

2/9/2015 - A new approach to vaccines, King 5 News

1/20/2015 - Kineta CEO on partnership with Seattle Children's to speed up pediatric drug treatments, Puget Sound Business Journal


1/15/2014 - Seattle biotech Kineta raises $1.3M for psoriasis, anti-viral, pain products, Puget Sound Business Journal

12/12/2014 - Ebola a wakeup call to disease threats, Puget Sound Business Journal

11/18/2014 - Partnering for Cures - Seattle Children's Research Institute and Kineta, Inc.: Alliance for Children's Therapeutics

11/07/2014 - Kineta wants to change biotech investing from 'a black box' to shorter, transparent model, Puget Sound Business Journal

11/2014 - Innovative Medicine: Researchers develop advanced treatments through Cutting-Edge Science, Alaska Airlines Magazine

10/27/2014 - Mining Venoms, Chemical & Engineering News

10/21/2014 - Kineta's plans: Research for Ebola, new funding for psoriasis clinical trials, Puget Sound Business Journal

8/02/2014 - WATCH: Seattle researchers hunting for Ebola cure, Fox News

8/02/2014 - VIDEO: Why is there no Ebola vaccine?, KIRO News

8/02/2014 - Seattle scientists seek an Ebola cure, The Seattle Times

7/11/2014 - Life Sciences: Who’s investing in biomedical firms? Doctors, Puget Sound Business Journal

6/12/2014 - Kineta, Seattle Children's Research Institute collaborate to develop medications for autoimmune diseases, Pharmaceutical Business Review

6/6/2014 - Collaborative KPI Therapeutics launches to beef up Kineta's pipeline, FierceBiotech

4/28/2014 - Baylor College of Medicine Releases Asthma Study using Kineta's ShK-186

3/13/2014 - angelMD Physician Network Invests in Kineta, Inc.

2/25/2014 - Kineta Wins Seattle Business Magazine’s Top “Achievement in Biopharmaceuticals” Award at Annual Health Care Leaders Salute

2/4/2014 - Novel Drugs Challenge Anti-TNFs for RA Treatment, Genetic Engineering & Biotechnology News


12/5/2013 - Kineta: Creative Financing Bridges the "Valley of Death", PharmaExec

11/4/2013 - Partnering For Cures Presentation - Kineta, Inc

11/4/2013 - Kineta teams up with UW researchers on $6.8M project to improve vaccines, Puget Sound Business Journal

10/31/2013 - A new model for drug development, Seattle Business

8/9/2013 - Streamlining Biotech Angel Returns, Private Wealth

7/30/2013 - Sea Creatures' Venom Could be Used to Treat Obesity, Pain, More, Komo News

7/12/2013 - Treatments from Toxins: New Drugs May Come from Some Dangerous Places, Time

7/12/2013 - Life Sciences: Biotechs finding ways to speed up payday, Puget Sound Business Journal

5/30/2013 - Autoimmune Drug Candidate Helps Mice Keep Trim Waists, BioWorld Today

5/22/2013 - VC: Kineta, Oligomerix gain fresh venture backing for R&D programs, FierceBiotech

5/21/2013 - Kineta, Scouring the World for Cash, Finds Oil Money, Xconomy

4/30/2013 - Seattle Biotech Kineta has a Plan for Faster Investor Returns, Puget Sound Business Journal

3/19/2013 - From Toxins to Therapeutics, TheScientist

2/7/2013 - RLB Holdings backs drug developer Kineta, AltAssets

2/5/2013 - Former oil trader, Yankees part-owner invests in Kineta, GeekWire

1/25/2013 - Two Kineta Drug Programs Featured in National Geographic Magazine


8/21/2012 - Kineta uses unorthodox strategy to push autoimmune drug into clinic, FierceBiotech


8/2011 - Seattle biotech gets NIH grant to combat rare viruses, Puget Sound Business Journal

3/2011 - VCs Not Welcome, Puget Sound Business Journal


7/2010 - Tax Credit from Feds on the Way, Puget Sound Business Journal

6/2010 - Seattle Biotech Wins Over Heartfelt Funding, Seattle Times


11/10/2009 - Kineta Rakes in Half of $13 Million Federal Contract, Xconomy

11/1/2009 - Start Up Profiles Kineta Business Model

8/1/2009 - Pharmaceutical Executive Profiles Kineta in "Hot Biotech" Issue

7/8/2009 - Kineta Acquires Multiple Sclerosis, Diabetes Drug Candidate, Xconomy

1/2009 - Seattle biotech Kineta funds research step by step, Seattle Times

Archived Press Releases


1/6/2017 - Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco


10/19/2016 - Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum

10/04/2016 - Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum

08/18/2016 - Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATE

07/12/2016 - Kineta Secures NIAID Funding to Expand Testing of Immune Modulators

06/10/2016 - Alliance for Children’s Therapeutics (ACT) Presents Dalazatide Data Demonstrating Positive Response in Lupus

05/16/2016 - Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting

05/12/2016 - KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference

05/11/2016 - KPI Therapeutics' Non-Opiate Pain Drug Effective in Neuropathic Pain and Burn Pain

05/05/2016 - Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

04/22/2016 - Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

03/31/2016 - Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu

03/22/2016 - Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress


11/10/2015 - Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus

11/9/2015 - Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting

7/29/2015 - Kineta Awarded NIH/NIAID Contract to Develop New Therapies for Viral Diseases

7/7/2015 - Kineta Chief Scientist Invited to Speak on Dalazatide Phase 1 B Clinical Trial

7/7/2015 - Kineta Presents New Data from its Non-Opiate Pain Drug Program

6/22/2015 - Kineta To Present At WBBA’s Life Sciences Innovation Northwest Conference

6/17/2015 - ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus

6/9/2015 - Kineta To Give Update On Dalazatide Clinical Trial Results At BIO International Meeting

6/4/2015 - Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections

5/12/2015 - Kineta Presents Data On Novel Antiviral Compounds Which Inhibit Broad Spectrum of Respiratory Diseases At International Antiviral Conference

5/5/2015 - Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases

4/21/2015 - University of Washington, Kineta, KPI form alliance to advance discoveries to bring new therapeutics to market

4/9/2015 - Kineta’s Adjuvants Boost Flu Vaccine Effectiveness in Data Presented at WorldVaccine Congress

3/25/2015 - 'Dalazatide' Chosen as New Generic Name for Kineta’s Lead Drug ShK-186

3/23/2015 - Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.

3/19/2015 - Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases

3/18/2015 - Kineta to Present at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference

3/9/2015 - Kineta Selected to Present New Anti-viral and Vaccine Adjuvant Data at International Conferences

2/17/2015 - Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences

1/21/2015 - Kineta Completes Enrollment of First Psoriasis Clinical Trial Using Novel ShK-186

1/05/2015 - Kineta to Present at Biotech Showcase 2015 in San Francisco, Wednesday, January 14, 10 am


11/18/2014 - Alliance for Children’s Therapeutics to Expand Pediatric Research to Multiple Sclerosis, Inflammatory Bowel Disease and Asthma

11/18/2014 - Kineta Presents Encouraging Safety and Efficacy Data for Lead Autoimmune Drug ShK-186 at Annual American College of Rheumatology Meeting

11/18/2014 - Kineta to Present at Elsevier Business Intelligence’s Therapeutic Area Partnership Conference in Boston

11/06/2014 - Alliance for Children’s Therapeutics to present its Pediatric Program at the Partnering for Cures Meeting Nov. 18

10/20/2014 - OHSU, Partners Kineta, U of Washington, VGTI Florida Awarded $10M NIH Contract To Develop New Vaccine Adjuvants

10/14/2014 - Kineta Announces the Opening of the First Psoriasis Clinical Trial Using Novel ShK-186

8/6/2014 - Cone Snail Peptide Reduces Pain and Prevents Nerve Damage in New Pain Study

6/11/2014 - First-of-Its-Kind Pediatric Research and Funding Collaboration to Speed Development of Medications for Autoimmune Diseases

6/10/2014 - Kineta To Make Corporate Presentations At Upcoming WBBA and BIO International 2014 Investor Conferences

6/05/2014 - Biotech Consortium Launches KPI Therapeutics, Inc., a New Collaborative Initiative to Speed Drug Development and Improve Investor Outcomes

5/19/2014 - Kineta’s Novel Antiviral Drugs Show Encouraging Efficacy Against Dengue And SARS Viruses

4/29/2014 - Kineta to present at Cavendish Global Health Forum

4/15/2014 - Kineta Inc. and RLB Holdings Announce New Joint Venture to Address High Need Therapeutics Including Autoimmune Diseases

1/27/2014 - Kineta Appoints Craig W. Philips Executive VP of Commercial Operations, Dan Eramian Senior VP Communications and Investor Relations


11/26/2013 - Kineta Announces Enrollment of First Subject in 1B Clinical Trial

11/4/2013 - University of Washington awarded new NIH contract to advance research on milestone development of vaccine immune boosters

10/29/2013 - Kineta President and CEO, Charles Magness to Speak on Company's Innovative Business Model Designed to Speed Translational Drug Development at Partnering For Cures Annual Conference

6/14/2013 - Kineta and Rosa form strategic alliance for next stage of clinical development of lead drug candidate Shk-186

5/27/2013 - UCI researchers demonstrate drug candidate ShK-186, derived from sea anemone venom, effective in anti-obesity studies

5/21/2013 - Global Oil Traders Fuel Kineta's Drug Pipeline

3/29/2013 - Kineta's Venom-derived drug programs featured in The Scientist magazine

2/5/2013 - RLB Holdings - Kineta Announce Investment Partnership

1/25/2013 - Two Kineta Drug Programs Featured in National Geographic Magazine


8/21/2012 - Kineta Announces Regulatory Clearance to Initiate a Phase 1 Clinical Trial for ShK-186

5/08/2012 - University of Washington, University of Texas Medical Branch and Kineta, Inc. Granted $8.1 Million for Biodefense Antiviral Drug Development


10/03/2011 - Kineta Scientists Present Novel Antiviral Research Findings at International Conference

7/19/2011 - The Iacocca Family Foundation Boosts Investment in Kineta's Autoimmune Program

4/11/2011 - NIH Extends Kineta's Contract to Develop New Drug Candidates


10/14/2010 - Kineta Wins New NIH Contract Aimed at Speeding Development of Novel Drug Classes

10/13/2010 - Windhover Announces the 2011 "Top Biopharma Projects to Watch"

6/7/2010 - The Iacocca Family Foundation and Kineta Announce New Partnership on Type 1 Diabetes Mellitus Drug Development Program

4/20/2010 - Kineta Scientist to Present Novel Antiviral Research Findings at International Conference

3/30/2010 - Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate


12/10/2009 - Kineta Partner Awarded UC Discovery Grant to Advance Preclinical Studies on Lead Autoimmune Therapeutic

11/10/2009 - Kineta, University of Washington partner on NIH-funded project to develop vaccine immune boosters

10/27/2009 - Kineta Announces Collaboration, Receives Funding and Investments for Multiple Programs

7/7/2009 - Kineta Acquires Novel Drug Candidates from Airmid for Potential Treatment of Multiple Sclerosis, Type 1 Diabetes and other Autoimmune Diseases

3/15/2009 - Kineta Inc. Executives Presenting at Invest Northwest


10/8/2008 - Kineta Receives SBIR Funding to Begin Novel Antiviral Research